Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at post‐treatment ‐ not reported · adults with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse events: treatment‐related neurotoxicity · Participants with PCNSL
It is very uncertain whether the intervention changes adverse events: treatment‐related neurotoxicity (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes infant Grade 3/4 Severe Adverse Events at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with severe delirium
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes adverse events including extrapyramidal effectsd compared with placebo plus haloperidol (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with chlorpromazine (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with lorazepam (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in adverse events including extrapyramidal effectse compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · hyperuricaemia in people with hypertension
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
1 finding from 1 review
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found